(UroToday.com) Dr. Walter Berger began his review with abstract 700O, the authors tested the predictive ability of three signatures: (1) a gene expression signature consistent with Teffector activity from IMmotion150 that when present enriched for responders to atezolizumab and bevacizumab. (2) a gene expression signature suggestive of Angiogenesis from IMmotion150 that when present in samples enriched for response to sunitinib. (3) the Kidney ccRCC Immune Classification (KIC) signature that identifies high or low levels of immune and stromal cell populations in each patient biopsy.